Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OMB to review FDA guidance

Executive Summary

The Office of Management and Budget issues a Jan. 18 bulletin to executive branch departments and agencies establishing policies and procedures for the development of significant guidance documents using FDA's guidance procedures as a model for these "good guidance practices." Each agency must designate an office to receive and address public complaints that the agency is not following procedures in the bulletin or is "improperly treating a guidance document as a binding requirement." The White House issues an executive order in conjunction with the OMB bulletin clarifying that OMB has authority to require notice and review of agency guidance documents...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel